title: How can we ameliorate irinotecan-associated diarrhea in children with poor compliance for oral cephalosporin?
authors.forename: Hiroki
authors.initials: H
authors.lastname: Nariai
authors.forename: Toshiji
authors.initials: T
authors.lastname: Shitara
authors.forename: Yuji
authors.initials: Y
authors.lastname: Oto
authors.forename: Tomo
authors.initials: T
authors.lastname: Natsumeda
authors.forename: Mayumi
authors.initials: M
authors.lastname: Taniuchi
authors.forename: Yoshitake
authors.initials: Y
authors.lastname: Sato
mesh_terms: D002166:Camptothecin / Q000009:adverse effects / Q000031:analogs & derivatives*; D002511:Cephalosporins / Q000627:therapeutic use*; D002648:Child; D003967:Diarrhea / Q000139:chemically induced / Q000517:prevention & control*; D006801:Humans; D000077146:Irinotecan; D008297:Male; D009447:Neuroblastoma / Q000628:therapy; D010349:Patient Compliance
chemical_list: D002511:Cephalosporins; D000077146:Irinotecan; D002166:Camptothecin